Virion Sialic Acid and HSV Ocular Infection

病毒体唾液酸和 HSV 眼部感染

基本信息

  • 批准号:
    7892440
  • 负责人:
  • 金额:
    $ 36.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-09-01 至 2012-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Herpes simplex virus is the leading cause of blindness due to infectious disease in the United States. Several antivirals are currently approved for treating HSV keratitis but there are problems with their use and some infections are refractory to treatment. These antivirals also cannot eliminate latent infection and recrudescent infections cause the majority of the blinding keratitis. Strategies that act on virions themselves to prevent attachment or entry into cells are viable strategies that have not been adequately studied. We previously described several peptides that inhibit HSV infection at low micromolar concentrations by inactivating virions in solution, inhibiting entry, and inducing a state of resistance in cells pre-treated with the peptides. These peptides also show little if any toxicity in the eye. Recently, we described a peptide, TAT-C, that inhibits HSV-1 infection and preliminary data suggests TAT-C binds to sialic acids on viral envelope proteins. A second critical finding recently published, is that sialic acids on one or more HSV-1 entry proteins are required for efficient entry into cells. These findings lead us to propose the overall hypothesis that TAT-C inhibits HSV fusion by binding to sialic acids on one or more entry proteins and that this binding interferes with a sialic acid mediated step in the entry process. The experiments in this proposal are designed to test this hypothesis and will be accomplished through four specific aims. 1) Test the hypothesis that TAT-C and sialic acids are involved in an entry step prior to fusion. 2) Test the hypothesis that TAT-C or removal of sialic acids from gB, gD, and/or gH/gL alters the function of the proteins. 3) Test the hypothesis that TAT-C or sialic acid removal alters the structure or stability of gB, gD, and/or gH/gL. 4) Test the hypothesis that sialic acids are critical for in vivo infection and that TAT-C has in vivo efficacy and the effect on latency. These studies will increase our understanding of the role of virion sialic acids in HSV-1 infection and could lead to the development of novel antiviral strategies for therapy. PUBLIC HEALTH RELEVANCE: We describe studies that will determine how sialic acids on HSV-1 envelope glycoproteins affect ocular disease and the role they play in viral entry. We will also test the mechanism whereby a peptide that binds sialic acid blocks HSV-1 infection. The studies will provide new insights into HSV-1 entry and could lead to the development of novel antivirals.
描述(由申请人提供):单纯疱疹病毒是美国传染病致盲的主要原因。目前有几种抗病毒药物被批准用于治疗HSV角膜炎,但它们的使用存在问题,一些感染难以治疗。这些抗病毒药物也不能消除潜伏感染和复发性感染导致大多数致盲角膜炎。作用于病毒粒子本身以防止附着或进入细胞的策略是可行的策略,但尚未得到充分的研究。我们之前描述了几种肽,它们通过灭活溶液中的病毒粒子,抑制进入,并在经过肽预处理的细胞中诱导抵抗状态,在低微摩尔浓度下抑制HSV感染。这些多肽对眼睛几乎没有毒性。最近,我们描述了一种抑制HSV-1感染的肽,TAT-C,初步数据表明TAT-C与病毒包膜蛋白上的唾液酸结合。最近发表的第二个重要发现是,一个或多个HSV-1进入蛋白上的唾液酸是有效进入细胞所必需的。这些发现使我们提出了一个总体假设,即TAT-C通过与唾液酸结合在一个或多个进入蛋白上抑制HSV融合,并且这种结合干扰了进入过程中唾液酸介导的步骤。本提案中的实验旨在验证这一假设,并将通过四个具体目标来完成。1)验证TAT-C和唾液酸在融合前参与进入步骤的假设。2)验证TAT-C或从gB、gD和/或gH/gL中去除唾液酸会改变蛋白质功能的假设。3)验证TAT-C或唾液酸去除会改变gB、gD和/或gH/gL的结构或稳定性的假设。4)验证唾液酸对体内感染至关重要的假设,以及TAT-C具有体内功效和对潜伏期的影响。这些研究将增加我们对病毒粒子唾液酸在1型单纯疱疹病毒感染中的作用的理解,并可能导致新的抗病毒治疗策略的发展。公共卫生相关性:我们描述了将确定HSV-1包膜糖蛋白上的唾液酸如何影响眼部疾病及其在病毒进入中所起作用的研究。我们还将测试一种结合唾液酸的肽阻断HSV-1感染的机制。这些研究将为1型单纯疱疹病毒的进入提供新的见解,并可能导致新型抗病毒药物的开发。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Curtis R Brandt其他文献

Curtis R Brandt的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Curtis R Brandt', 18)}}的其他基金

Biological Treatment of Bacterial Keratitis
细菌性角膜炎的生物治疗
  • 批准号:
    9409020
  • 财政年份:
    2015
  • 资助金额:
    $ 36.75万
  • 项目类别:
Virulence Genes in Herpes Simplex Virus Ocular Infection
单纯疱疹病毒眼部感染的毒力基因
  • 批准号:
    8481769
  • 财政年份:
    2013
  • 资助金额:
    $ 36.75万
  • 项目类别:
Virulence Genes in Herpes Simplex Virus Ocular Infection
单纯疱疹病毒眼部感染的毒力基因
  • 批准号:
    8812864
  • 财政年份:
    2013
  • 资助金额:
    $ 36.75万
  • 项目类别:
Virulence Genes in Herpes Simplex Virus Ocular Infection
单纯疱疹病毒眼部感染的毒力基因
  • 批准号:
    8616377
  • 财政年份:
    2013
  • 资助金额:
    $ 36.75万
  • 项目类别:
Pathogenesis of Vaccinia virus keratitis
痘苗病毒性角膜炎的发病机制
  • 批准号:
    8287222
  • 财政年份:
    2012
  • 资助金额:
    $ 36.75万
  • 项目类别:
Pathogenesis of Vaccinia virus keratitis
痘苗病毒性角膜炎的发病机制
  • 批准号:
    8445214
  • 财政年份:
    2012
  • 资助金额:
    $ 36.75万
  • 项目类别:
Virion Sialic Acid and HSV Ocular Infection
病毒体唾液酸和 HSV 眼部感染
  • 批准号:
    7668413
  • 财政年份:
    2008
  • 资助金额:
    $ 36.75万
  • 项目类别:
Virion Sialic Acid and HSV Ocular Infection
病毒体唾液酸和 HSV 眼部感染
  • 批准号:
    8123318
  • 财政年份:
    2008
  • 资助金额:
    $ 36.75万
  • 项目类别:
Virion Sialic Acid and HSV Ocular Infection
病毒体唾液酸和 HSV 眼部感染
  • 批准号:
    7523400
  • 财政年份:
    2008
  • 资助金额:
    $ 36.75万
  • 项目类别:
Core Grant for Vision Research
视觉研究核心资助
  • 批准号:
    6945497
  • 财政年份:
    2005
  • 资助金额:
    $ 36.75万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 36.75万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 36.75万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 36.75万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 36.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 36.75万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 36.75万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 36.75万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 36.75万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 36.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 36.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了